Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026

Stock Information for Telomir Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.